Medtronic (NYSE:MDT) revealed the details today of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.
American College of Cardiology
Medtech gears up for Medtronic’s RDN trial results | MassDevice.com On Call
The American College of Cardiology gets a new CEO
Since when does a pharmaceutical executive become CEO of the American College of Cardiology (ACC)?
D+Vice Talk – March 21, 2013
Welcome to the latest edition of the MassDevice.com’s D+Vice Talk, our new webcast, in which we review medical device stories from the last week.
In this episode we start with updates from Capitol Hill, review highlights from the American College of Cardiology conference, consider the mixed FDA reports for Abbott’s MitraClip heart implant and debate Dr. Robert Hauser’s controversial proposal to overhaul the FDA.
Find all of today’s referenced stories here:
Looking back on a pretty sedate ACC
Sometimes the major annual medical meetings are jam-packed with significant and market-moving data. And then sometimes they’re like this year’s American College of Cardiology conference, with relatively limited useful data from an investing perspective.
MassDevice.com +7 | The top 7 med-tech stories for the week of March 11, 2013
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Study: Renal denervation for hypertension may also help stabilize heart rhythms
Renal denervation technologies, which are already the focus of much clinical attention for the potential to treat high blood pressure without drugs, may have a bonus side-effect in keeping the heart in check, according to researchers.
ACC.13 Roundup: A big week for Medtronic’s Symplicity high blood pressure device
Transcatheter mitral valves are going to the dogs
The field of transcatheter mitral valve repair may move more quickly in pet populations than it does in human medicine, according to a presentation during this week’s American College of Cardiology conference in San Francisco.
Researchers are hard at work on a technology, called MitralSeal, they they hope to bring to market to treat mitral valve regurgitation in dogs.
TAVI: Sapien going strong at 3 years, but leak risk remains “overwhelmingly” higher
Updated March 19, 2013, at 11:30 a.m. to reflect that the quote in paragraph 6 came from an ACC press release, not an Edwards press release.
ACC defends cancellation as docs lament missing Boston Scientific presentation | MassDevice.com On Call
MASSDEVICE ON CALL — The embargo breach that got Boston Scientific’s (NYSE:BSX) PREVAIL clinical trial results pulled from the lineup at the American College of Cardiology conference this weekend was "an honest mistake," according to the company, but conference organizers don’t regret canceling the presentation.